English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Trending Topics
    Sensex Live RPP Infra Projects Shares Zydus Lifesciences Shares Amanta Healthcare IPO Allotment LIVE GST on Health Insurance

    business

    With Sun Pharma-Merck striking JV, why is SPARC shining?

    According to CNBC-TV18's research analyst Ekta Batra it's SPARC which has emerged as the winner from this deal between Sun Pharma and Merck. They are targeting a portfolio of around 12 drugs in around 100 countries but the focus is expected to be the top 10 countries which are expected to contribute around 80% of revenues.

    first published: Apr 13, 2011 02:37 pm

    LATEST VIDEOS

    Watch More →

    A collection of the most-viewed Moneycontrol videos.

    Watch and Follow our leading shows

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347